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ABSTRACT 
 
 Survivin is an Inhibitor of Apoptosis Protein (IAP), which is highly expressed in a 
number of human malignancies. It is a developmentally regulated gene that is expressed 
during embryogenesis, but silenced in normal adult tissue. Since its discovery in 1997, 
survivin function has evolved to include regulation of spindle assembly in mitosis. 
Melanoma arises in epidermal melanocytes, and is the most lethal dermatologic cancer 
due to its highly metastatic nature. In melanoma, expression of survivin has been heavily 
correlated to advanced disease stages and poor patient prognosis. Targeting of survivin in 
melanoma cells leads to induction of apoptosis in vitro and reduction of tumor growth in 
vivo. 
While the anti-apoptotic and mitotic roles of survivin have been extensively 
studied, the work documented in this dissertation describes a novel basis for survivin 
function in melanoma metastasis. Chapter 2 details a study which showed that survivin 
increases melanoma cell migration and invasion via Akt-dependent upregulation of α5 
integrin. I also demonstrate that overexpression of survivin increases melanoma colony 
formation in soft agar, and this effect could be abrogated by knockdown of α5 integrin by 
RNA interference. These findings demonstrate that survivin can enhance cellular 
functions which are critical to the metastatic process in melanoma. To further investigate 
the functional role of survivin and α5 integrin in melanoma metastasis, I used a 
 iv  
xenograft mouse model to determine the in vivo effect of survivin overexpression and 
subsequent upregulation of α5 integrin on melanoma metastasis (Chapter 3). The studies 
show that while survivin overexpression does not result in increased tumor proliferation 
or decreased apoptosis, it does cause increased metastasis of melanoma cells in vivo and 
this requires upregulation of α5 integrin. Taken together, this dissertation presents data to 
support an additional role for survivin function in melanoma metastasis which is α5 
integrin-dependent. 
 In summary (Chapter 4), I will discuss future research avenues looking 
mechanistically at how survivin upregulates α5 integrin and mediates melanoma 
metastasis. Additionally, I will also discuss therapeutic targeting of survivin and α5 
integrin in melanoma and how the knowledge gained in this study may contribute to such 
efforts. 
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CHAPTER 1 
INTRODUCTION 
2 
 
Biology of human melanocytes 
The skin is the largest organ in the body, and is the body’s direct barrier with the 
physical environment. As such, the skin has a myriad of functions including protecting 
the body from physical, chemical or microbial insults.
1
 The skin serves to regulate body 
temperature; shield the body from most solar ultraviolet radiation (UVR); and modulate 
immune responses to pathogens coming in contact with the body.
1
 Skin is stratified into 
the epidermis, which is the external epithelial layer of skin; the dermis, a thicker and 
more complex layer below the epidermis; and the hypodermis, which is a layer of fatty 
tissue connecting the dermis to underlying skeletal components.
1
 Approximately 95% of 
the cells found in the epidermis are keratin-containing cells known as keratinocytes 
(Figure 1.1).
2
 The epidermis also contains two other cell types: Langerhans cells and 
Merkel cells, which are involved in immune response and mechanosensation 
respectively.
3, 4
 
Melanocytes are specialized dendritic cells, which can be found in the Stratum 
basale layer of the epidermis of skin (Figure 1.1). Melanocytes produce the 
biochemically stable pigment melanin in lysosome-related organelles known as 
melanosomes,
5
 which are then transferred to overlying keratinocytes through cell-to-cell 
contact.
6
 Melanocytes and progenitor keratinocytes, found in the deeper layers of the 
epidermis proliferate at a slow rate. However, keratinocytes in the upper epidermis 
proliferate rapidly, and are eventually shed through desquamation.
6
 Melanocytes also 
occur in other areas of the body such as: hair follicles, the inner ear, and the eye.
6
 They 
interact with neighboring cells in these organs to mediate functions distinct from those of 
epidermal melanocytes.
7, 8
 
3 
 
 
Figure 1.1 Structure of the epidermis. Melanocytes and progenitor keratinocytes can be 
found in the Stratum basale layer of the epidermis. As the major cell type in the 
epidermis, melanin-containing keratinocytes also occupy the upper layers of the 
epidermis.
1
 
 
 
 
 
 
 
                                                          
1
 Modified from: Raj D, Brash DE, and Grossman D. Keratinocyte Apoptosis in Epidermanl Development 
and Disease. Journal of Investigative Dermatology.2006; 126:243:257. 
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Melanoblasts are melanocyte precursor cells and are derived from the neural 
crest.
1
 They develop starting in the second month of human embryogenesis and migrate 
through the mesenchyme as the embryo develops.  By the 18
th
 week of embryonic 
development, melanoblasts arrive in the epidermal layer of the skin.
1
 Successful 
deposition, development and function of melanoblasts in the epidermis are dependent on 
a cohort of at least 25 genes including Kit; mutations in which lead to developmental 
pigmentary diseases such as piebaldism.
6, 9
 
Through regulation of pigment production, melanocytes are able to carry out their 
photoprotective function in which melanin absorbs and refracts harmful UVR.
1
 
Consequently, individuals with lightly pigmented skin have a 15 - to 70 - fold increased 
risk of skin cancers over individuals with darkly pigmented skin, primarily due to the 
damaging effects of UVR.
10
 There have been a number of studies which propose that 
melanocytes are not simply pigment producing cells. It has been shown that melanocytes 
produce a range of signaling molecules such as cytokines,
11
 pro-opiomelanocortin 
(POMC) peptides,
12
 catecholamines
13
 and also nitric oxide in response to UVR.
14
 
Receptors for these signaling cues can be found on skin cells such as keratinocytes, and 
fibroblasts; making them potential targets for these secretory products.
15
 This implies that 
melanocytes may act as important local regulators of a range of skin cells. 
 
Malignant melanoma 
Melanoma is a dermatologic cancer that develops in response to genetic or 
environmental insults in melanocytes.
16
 Malignant melanoma is a significant and growing 
public health burden in the United States (US). In 2010, an estimated 68 000 cases were 
diagnosed, with roughly 9 000 deaths.
17
 Melanoma incidence in the US has increased 
5 
 
exponentially since the 1930s.
18
 It is estimated that by 2015 the lifetime risk of invasive 
melanoma in the US will be 1 in 50, up from 1 in 1500 in the 1930s.
18
 
 Fortunately, there has been steady improvement in the 5-year survival rate for 
localized melanoma, increasing from 82% in 1979 to 92% in 2002.
17
 This is primarily 
because localized, nonmetastatic melanoma is curative by surgical excision. This 
favorable survival rate has also been aided by an increase in early detection, which in turn 
leads to decreased healthcare cost. It is estimated that 90% of the cost of melanoma 
therapy in the US is from treatment of patients with metastatic disease.
19
 Patients with 
metastatic disease are also plagued by a poor 5-year survival rate (< 10%).
20
 This again 
highlights the importance of early detection of melanoma. 
 The most common genetic risk factors for melanoma are associated with 
pigmentation phenotypes, such as fair skin, blond or red hair and blue eyes, as well as 
multiple melanocytic nevi (moles).
21
 Most melanoma cases occur sporadically, with 
familial melanoma accounting for less than 10% of cases.
22
 Cyclin-dependent kinase 
inhibitor 2A (CDKN2A), which encodes both p16 and p19
ARF
 tumor suppressor genes, 
has been identified as the most commonly altered gene in familial melanoma.
22
 The 
predominant risk factor for melanoma is exposure to the DNA-damaging effects of UVR, 
from excessive sun exposure or from tanning beds.
18
 
 Developed by Drs Clark, Elder, and Guerry, the Clark Model for melanoma 
progression describes the histopathologic changes that may accompany the 
transformation from nevi (moles) to malignant and metastatic melanoma.
23
 In the initial 
stages, melanocytic nevi become dysplastic and progress to a radial growth phase (RGP) 
where tumor cells are able to rapidly proliferate and spread laterally in the epidermis 
6 
 
(Figure 1.2). Lesions progress to an aggressive vertical growth phase (VGP), in which 
tumor cells invade the dermis and lead to the metastatic spread of the disease.
23
 The 
Clarke Model is a linear progression representation of melanomagenesis. However, it 
must be noted that this model is not typical of how melanoma usually develops. 
Melanoma most often arises in melanocytes de novo in response to UV-induced DNA-
damage.
24
 
The phenotypic changes documented in the Clarke Model are representative of 
the underlying genetic and proteomic changes that occur to facilitate the transitions from 
dysplastic nevi to metastatic melanoma (Figure 1.2).
23
 More than 70% of melanoma cases 
have been found to harbor activating mutations in key molecules like BRAF, NRAS and 
c-Kit.
25
 These molecules are key intermediaries in signaling pathways that are initiated at 
the cell surface in response to growth factor or other external stimuli activation of 
transmembrane receptors. In response, cells are directed to proliferate, differentiate, 
senesce, move or die. 
 
Common genetic alterations in signaling pathways in melanoma 
In melanoma, the RAS/RAF/MEK/ERK (MAPK) and the PI3K/PTEN/AKT 
(AKT) networks are two major signaling pathways that are constitutively activated 
through genetic alterations.
26
 Mutations affecting RAF, RAS and PTEN result in 
deregulation of apoptosis, proliferation, angiogenesis and invasion (Figure 1.3);
26
 which 
is essential for cancer metastasis (Figure 1.4).
27
 Metastasis is a complex set of processes 
that involves tumor cell detachment and invasion from the primary tumor, tumor cell 
transport and survival in the circulatory system, arrest in and extravasation from the 
vasculature, culminating in proliferation and outgrowth in distant sites (Figure 1.5).
28
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Figure 1.2 Molecular events in melanoma progression. Genetic and proteomic changes 
aid in the progression of melanoma from the initial stages of the disease (dysplatic nevus) 
to metastatic melanoma. BRAF mutations and consequent overactivation of the MAPK 
pathway is evident throughout disease progression. PTEN loss also helps tumor 
progression by increasing activity of the PI3K/AKT pathway. The vertical growth phase 
and metastatic melanoma are characterized by changes in cell adhesion receptor proteins 
like integrins and cadherins. These transmembrane proteins help the cells to create and 
remodel the extracellular matrix to help tumor cells progress. The expression of survivin 
increases as the disease progresses to aid in apoptotic resistance and metastasis.
2
 
 
 
 
 
 
 
                                                          
2 Modified from: Zaidi MR, Day CP, and Merlino G. From UVs to Metastases: Modeling Melanoma 
Initiation and Progression in the Mouse. Journal of Investigative Dermatology. 2008; 128:2381-2391. 
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Figure 1.3 The MAPK and PI3K/AKT signaling pathways. These are two major 
signaling pathways that control various cellular functions. Activation of cell surface 
receptors (R) results in phosphorylation (P) and activation of RAS. In turn, RAS can 
activate the MAPK cascade through phosphorylation of RAF. RAS also activates the 
PI3K/AKT pathway through direct binding to PI3K. The AKT pathway may be 
attenuated by PTEN inhibition of the conversion of Phosphatidylinositol di-Phosphate 
(PIP2) to Phosphatidylinositol tri-Phosphate (PIP3). Genetic or epigenetic alterations in 
signaling components (*) allow for tumorigenesis and metastasis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
9 
 
 
Figure 1.4 The hallmarks of cancer. Through deregulation of physiologic processes 
used by the cell to maintain homeostasis, tumor cells acquire functionalities that facilitate 
tumor progression and metastasis.
3
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                          
3
 Modified from: Hanahan D, and Weinberg RA. Hallmarks of Cancer: The Next Generation. Cell. 2011; 
144:646-674. 
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Figure 1.5 The sequential process of metastasis. Metastasis is a complex network of 
processes that facilitate the spread of tumor cells from the primary site. Tumor cells 
become detached from the primary tumor and invade through the basement membrane. 
Tumor cells are disseminated through the circulatory or lymphatic system. Tumor cells 
that survive this transport can then arrest in other organs where they undergo 
extravasation. Subsequently, tumor cells interact with the microenvironment to help 
establish new tumor colonies.  
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There is a significant amount of crosstalk that occurs between the MAPK and 
PI3K/AKT signaling pathways. RAS is a focal point in these pathways and can enhance 
cell proliferation through regulation of MAPK; whereas it can elicit an anti-apoptotic 
response through regulation of PI3K (Figure 1.3).
29
 The RAS family of proto-oncogenes 
consists of: HRAS, KRAS, and NRAS.
30
 NRAS is the most commonly mutated isoform 
and is present in approximately 20% of all melanoma cases.
31
 
One downstream effector of RAS is RAF, which is a component of one arm of the 
Mitogen Activated Protein Kinase (MAPK) signaling network.
32
 Through sequential 
phosphorylation events, MAPK signaling components are activated and regulate cell 
proliferation, differentiation, migration and apoptosis.
33
 The RAF kinase family consists 
of three isoforms: ARAF, BRAF, and CRAF.
34
 RAFs are serine/threonine 
phosphotransferases that initiate the MAPK pathway through phosphorylation of MEK. 
In turn, MEK phosphorylates and activates ERK (Figure 1.3).
35
 ERK targets include the 
transcription factor Elk-1,
36
 cytoskeletal proteins such as Paxillin,
37
 and other kinases like 
Ribosomal S6 Kinase,
38
 which help to execute various cellular functions. It is therefore 
understandable how mutations in MAPK components are advantageous to tumor cells. 
BRAF mutations are found in approximately 60% of all melanoma cases and the 
majority of BRAF mutations in melanoma is a missense mutation that switches Valine to 
Glutamic Acid at codon 600 (V600E).
35
 The BRAF
V600E
 mutation has been detected in 
benign nevi, primary, and metastatic melanomas,
39
 indicating that it may be a driver of 
early events in melanomagenesis (Figure 1.3). However, dysplastic nevi may remain 
dormant for extended periods of time before progressing to more advanced melanoma, 
suggesting that a second genetic ‘hit,’ such as loss of a tumor suppressor (ex. p53) is 
12 
 
required for BRAF mutations to facilitate tumor progression. Using a zebrafish model, 
studies have shown that melanocyte-specific expression of BRAF
V600E
 can induce 
hyperproliferation of melanocytes, akin to dysplastic nevi in humans.
40
 However, 
combination of p53 loss with BRAF
V600E
 was required for frank melanoma.
40
  
 Another commonly deregulated signaling pathway in malignant melanoma is the 
PI3K/PTEN/AKT pathway. Like the MAPK network, PI3K/AKT also modulates cell 
proliferation and survival.
41
 The PI3K pathway can be activated in response to cell 
surface receptor (ex. Receptor Tyrosine Kinase; RTK) activation, or from direct binding 
of RAS to PI3K.
30
 Through generation of the second messenger molecule 
phosphatidylinositol tri-phosphate (PIP3), AKT is phosphorylated and hence activated 
(Figure 1.3).
30
 Activated AKT is an important downstream effector of PI3K, which 
regulates the balance between cell survival and cell death.
42
  
The PI3K pathway is negatively regulated by the Phosphatase and Tensin 
homolog (PTEN) gene.
22
 PTEN dephosphorylates PIP3, directly opposing PI3K function 
and thereby inhibiting phosphorylation of AKT (Figure 1.3).
30
 As PI3K itself is rarely 
mutated in melanoma,
43
 loss of PTEN is one mechanism by which PI3K/AKT signaling 
is constitutively activated in melanoma. PTEN loss through gene deletion or epigenetic 
silencing (via promoter DNA methylation) has been detected in 10% to 30% of cutaneous 
melanomas.
44
 Mutations in RAS can also lead to ectopic activation of PI3K/AKT 
pathway in melanoma.
30
  
Activated AKT is detected in approximately 67% of melanoma cases,
45
 and its 
expression is inversely correlated to patient prognosis.
46
 Additionally, overexpression of 
activated AKT in melanoma cells causes transition from the early stage RGP to the more 
13 
 
aggressive VGP form in vivo.
46
 In addition to regulating apoptosis, activated AKT has 
also been shown to mediate melanoma cell migration and invasion.
47, 48
 These signaling 
networks have been demonstrated to be essential for melanoma tumor growth and 
metastasis. The alterations in the MAPK and PI3K/AKT pathways have opened the door 
to the development of targeted therapies in melanoma. The next section is a discussion on 
therapeutic approaches that include targeting of these signaling pathways. 
 
Therapeutic options for malignant melanoma 
Until 2011, Dacarbazine (DTIC), high-dose interleukin-2 (IL-2), and hydroxyurea 
were the only Food and Drug Administration (FDA) approved therapies for metastatic 
melanoma.
25
 However, none of these treatment modalities have had significant success in 
curtailing metastatic melanoma. DTIC is an alkylating chemotherapeutic agent which 
induces cell death. Low levels of efficacy and a lack of data to support a survival benefit 
means that DTIC has a minimal effect in patients with metastatic melanoma. High-dose 
IL-2 treatments are based on augmenting the numbers and activity of natural killer T-
cells. However, this form of immunotherapy has only proven effective for a small 
percentage of patients. Pretreatment prediction of IL-2 efficacy is unknown and the high 
risk for multi-organ failure makes this treatment option less than ideal. 
 However, 2011 proved to be an historic year for the treatment of metastatic 
melanoma with two different drugs gaining FDA approval. Vemurafenib (Zelboraf) is a 
RAF kinase inhibitor which targets the BRAF
V600E
 mutant prevalent in melanoma.
49
 This 
targeted therapy has shown efficacy and was the first drug ever approved which showed 
significant improvement in overall survival in metastatic melanoma.
25
 Vemurafenib acts 
by inhibiting phosphorylation of MEK and ERK, leading to G1 phase cell-cycle arrest 
14 
 
and apoptosis.
50, 51
 While early clinical trials have demonstrated in excess of an 80% 
response rate among patients with V600E-positive melanomas, patient relapse is quite 
frequent due to acquired resistance to BRAF inhibition.
49
  
Tumor cells are able to develop resistance to BRAF inhibition through a number 
of mechanisms which are dependent or independent of RAF.
52
 RAF dependent 
mechanisms of resistance include: (i) upregulation of NRAS
53
 or mutations in KRAS,
54
 
which causes reactivation of MEK/ERK signaling; or (ii) paradoxical activation of the 
MAPK pathway, where blocking mutated BRAF results in CRAF-mediated activation of 
MEK.
55
 Resistance can also be acquired through bypass of RAF signaling. COT/TPL2, is 
a kinase which functions upstream of MEK and has been shown to activate ERK through 
MEK-dependent mechanisms that do not require RAF signaling.
56
 Clinical trials are now 
underway to develop strategies to overcome resistance to RAF inhibition via combination 
of RAF and MEK inhibitors.
25
 
The second drug approved, Ipilimumab (Yervoy), is an anti-Cytotoxic T-
Lymphocyte associated Antigen 4 (α-CTLA-4) monoclonal antibody.57 This drug elicits a 
therapeutic response through hyperactivation of natural killer T-cells in the immune 
system.
57
 However, adverse immunologic side effects and limited efficacy have 
hampered Ipilimumab.
58
 Less than 10% of patients with metastatic melanoma had 
complete or partial responses to this immunologic drug. However, patients that responded 
favorably had long-lasting disease control or remissions.
57
  
The shortcomings in viable therapeutic options for metastatic melanoma highlight 
two key facts regarding this public health issue: (i) Early detection is critical in curtailing 
melanoma morbidity and mortality and (ii) A better understanding of the molecular 
15 
 
events regulating melanoma progression is fundamental for the development of more 
effective therapies for metastatic melanoma. The next section will focus on the molecular 
biology and function of Survivin, a protein which has been found to play a critical role in 
melanoma biology. 
 
Biology of survivin: structure and subcellular localization
4
 
First cloned in 1997, survivin is the smallest member of the inhibitor of apoptosis 
protein (IAP) family.
59
  The survivin gene spans approximately 14.7 kb on chromosome 
17, and its transcription is initiated from a TATA-less, GC-rich promoter.  Transcription 
generates full-length (wild-type) survivin, along with four other splice variants.
60
  Unlike 
other members of the IAP family such as X-linked Inhibitor of Apoptosis Protein (XIAP), 
and Cytosolic Inhibitor of Apoptosis Protein 1 (cIAP1), survivin has a single Baculoviral 
IAP Repeat (BIR) domain and also lacks the Really Interesting New Gene (RING) finger 
domain characteristic of other IAPs (Figure 1.6).
61
  Additionally, survivin lacks a 
Caspase-Associated Recruiting Domain (CARD), which is critical for other IAP family 
members to bind and inactivate caspases, the effectors of apoptosis (Figure 1.6).
62
 
Survivin is also distinguished from other IAPs because of its bi-functionality as a 
regulator of both apoptosis and mitosis.
63
 
Expression of survivin is developmentally regulated as it is ubiquitously 
expressed in fetal tissues, silent in most adult tissues, and then re-expressed in most 
cancers.
64
  More recent studies using sensitive detection methods have demonstrated 
survivin expression in some normal adult tissues.  These include vascular endothelial  
                                                          
4
 Reprinted with permission from: McKenzie JA, and Grossman D. Role of the Apoptotic and Mitotic 
Regulator Survivin in Melanoma. Anticancer Research. 2012; 32:397-404. 
   Reprinted here is a portion of the above article. 
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Figure 1.6 Structure of inhibitor of apoptosis proteins (IAP). Inhibitor of apoptosis 
proteins are classified based on the presence of the Baculoviral IAP Repeat (BIR) 
domain. IAPs like x-linked inhibitor of apoptosis protein (XIAP) and cytosolic inhibitor 
of apoptosis protein 1 (cIAP1) are much larger proteins at 497 and 604 amino acids (aa), 
respectively. They both contain the Really Interesting New Gene (RING) motif which is 
a zinc finger domain that regulates ubiquitination. cIAP1 also contains a Caspase 
Activating and Recruiting Domain (CARD) to mediate binding and activation of 
caspases. With only 142 amino acids, survivin is a smaller and unique member of the 
family as it contains only a single BIR domain. 
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cells,
65
 and developing hematopoietic and immune cells.
66-68
  Although there are five 
distinct isoforms of survivin, the predominant and most studied is the wild-type full 
length survivin.  There has been speculation that the varied cellular functions may be 
attributed to different splice variants but this has been difficult to determine given the low 
level of expression of the minority variants.
69
 
There are distinct subcellular pools of survivin located in the cytosol, 
mitochondria, and nucleus.
70, 71
  These subcellular pools are believed to be strongly tied 
to its varying cellular functions.  Studies have demonstrated that the nuclear pool 
mediates survivin function in mitosis, while the cytosolic and mitochondrial fractions are 
responsible for its anti-apoptotic function.
71-73
 Survivin shuttles from the nucleus to the 
cytoplasm under the control of an evolutionarily conserved Crm1 nuclear export signal 
(NES).  When this NES is mutated, survivin is trapped in the nucleus, proper cell division 
does not occur and the anti-apoptotic function of survivin is also lost.
74
 
In tumor cells, survivin localizes to the inner mitochondrial membrane.
71
  In 
response to apoptotic stimuli, survivin is trafficked from the mitochondria to the cytosol 
where it can inhibit apoptosis.
71
  It has been shown that phosphorylation of survivin on 
residue Ser20 by Protein Kinase A occurs in the cytosol but not in the mitochondria, and 
this differential phosphorylation regulates tumor cell apoptosis by modulating the 
interaction of survivin with x-linked inhibitor of apoptosis protein (XIAP).
75
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Regulation of Survivin expression and 
posttranslational modifications
5
 
Numerous studies have identified various genetic elements which exert 
transcriptional and translational control over survivin expression.  Basal survivin gene 
expression is mediated through binding of SP1 to the GC rich region of the survivin 
promoter.
76
  A role for p53 in suppressing survivin expression has been shown,
77
 and our 
lab’s more recent work has demonstrated that knockdown of either p53 or Rb protein in 
melanocytes is sufficient for survivin induction.
78
  Although E2F2 has been previously 
characterized as a positive regulator of transcription, our lab identified a novel functional 
E2F2-binding site in the survivin promoter and found that E2F2 acts downstream of Rb 
to function as a negative regulator of survivin.
78
  It was also found that mutation of either 
the p53- or E2F2-binding sites in the survivin promoter increased transcription.
78
  These 
findings suggest that perturbations in the p53 or Rb pathways, which may occur as a 
result of INK4A loss in melanoma,
79
 can result in upregulation of survivin expression. 
There may also be a role for other tumor suppressors in the regulation of survivin 
expression in melanoma.  Caveolin-1 inhibits survivin gene transcription by preventing 
TCF/LEF promoter binding in an E-cadherin-dependent manner, and this mechanism is 
operative in mouse melanoma cells leading to increased apoptosis.
80
  Thus loss of E-
cadherin expression, as frequently occurs in melanoma, may result in reduced activity of 
Caveolin-1 and consequent upregulated survivin expression.  Epigenetic modifications 
may also be important in regulating survivin expression, as histone deacetylation can 
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direct methylation and silencing of the survivin promoter,
81
 although this pathway has not 
been investigated in melanoma.  
Several posttranslational modifications have been described which regulate 
survivin stability and function, namely phosphorylation and ubiquitination. Cyclin-
dependent Kinase 1-mediated phosphorylation of Thr34 is vital for survivin anti-
apoptotic function,
82
 and our lab has shown that a nonphosphorylatable Thr34Ala mutant 
blocks growth of human melanoma tumor xenografts.
83,84
 Survivin is also phosphorylated 
at Ser20 by Polo-like Kinase 1
85
 and at Thr117 by Aurora B Kinase;
86
 while these 
modifications are important for mitotic regulation by survivin, their role in melanoma has 
not been investigated.   
Survivin is highly expressed in the G2M phase of the cell cycle, and degraded via 
the ubiquitin-proteasome pathway during G1.
87
 In various cell types, EGF and 
Cyclooxygenase-2 signaling inhibit its ubiquitin-mediated degradation, leading to 
increased apoptotic resistance.
88, 89
 On the other hand, X-linked Inhibitor of Apoptosis 
(XIAP)-Associated Factor 1 (XAF1) is a putative tumor suppressor that can reverse the 
anti-apoptotic activities of survivin by targeting it for ubiquitination.
90
  Finally, 
interaction of survivin with the chaperone protein Hsp90 has been shown to increase 
survivin stability and threshold for apoptotic stress in cancer cells.
87
 
 
Survivin expression as a prognostic factor in melanoma
6
 
The expression of survivin at each stage of melanomagenesis has been 
characterized.  Survivin is absent in normal melanocytes, but our lab has shown it to be 
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expressed in a broad spectrum of human melanomas (including localized and metastatic) 
and melanocytic nevi including dysplastic, neurotized intradermal, and Spitz nevi.
91, 92
  In 
dysplastic nevi, survivin is primarily localized to the cytosol, although some nevi may 
show nuclear survivin.
93
  A more recent study found positive nuclear immunoreactivity 
for survivin in a large subset of melanomas but much less frequently in common and 
dysplastic nevi.
94
  In addition, nuclear survivin immunoreactivity was significantly less 
common in acral versus other melanoma types, in which nuclear survivin staining 
significantly correlated with poor survival.
94, 95
 
Survivin expression is also induced upon melanocyte transformation or in 
response to disruption of the tumor suppressor genes TP53 (p53) or Retinoblastoma 
(Rb).
78
 Molecular profiling has identified survivin as a marker of poor prognosis and as 
an indicator of treatment resistance.
63
  Additionally, several studies have indicated that 
survivin can serve as a biomarker for a number of malignancies.
96-98
  With respect to 
melanoma, survivin expression in sentinel lymph nodes of melanoma patients is inversely 
correlated with progression and mortality, as 61.5% of stage III patients who exhibited 
survivin-positive sentinel nodes (by RT-PCR) died from their disease.
99
  On the other 
hand, all melanoma patients with survivin-negative sentinel nodes were still alive after 
the 5-year observation period.
99
  Survivin levels may also be predictive of treatment 
outcome in melanoma, as one study reported that in patients with recurrent metastatic 
melanoma, lower levels of survivin are associated with significantly improved survival in 
patients who receive postoperative adjuvant immunotherapy.
100
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Survivin function in cell division
7
 
Disruption of survivin function, at least in malignant cells, results in cell cycle 
defects including multipolar mitotic spindles, failure of cytokinesis, and formation of 
multinucleated cells.
101
  Expression of a dominant-negative survivin mutant in melanoma 
cells results in loss of G2/M DNA content and in reduced proliferation in vitro and in 
vivo.
83, 91
  Survivin is a chromosomal passenger protein that interacts with other 
passenger proteins including Aurora B Kinase and Inner Centromere Protein (INCENP) 
to facilitate movement of the chromosomal passenger protein complex from the inner 
centromere during prometaphase to the midbody during cytokinesis.
102, 103
  Survivin is 
also involved in microtubule spindle assembly and organization.
104
  It is plausible that 
survivin may help tumor cells that have sustained DNA damage to bypass cell cycle 
checkpoints and proceed with cell division. 
 
Survivin function in apoptosis
8
 
Consistent with its unique protein structure compared to other IAPs, survivin 
exerts its anti-apoptotic function in a different manner.  While conventional IAPs such as 
XIAP, Livin, and cIAP1/cIAP2 directly bind to pro-caspases, ubiquitinate them, or 
prevent their proteolytic cleavage and subsequent activation,
105
 survivin does not appear 
to directly bind to caspases.  Rather, survivin exerts anti-apoptotic control by binding to 
and stabilizing XIAP, which inhibits caspase-9.
106
 Survivin-mediated inhibition of 
caspase-9 has also been shown to be dependent on binding to a co-factor Hepatitis B X-
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interacting Protein (HBXIP)
107
.  The anti-apoptotic function of survivin is negatively 
regulated by release of SMAC/DIABLO from mitochondria, upon triggering the intrinsic 
cell death pathway.
108
  
Our laboratory has characterized the anti-apoptotic role of survivin in normal 
human melanocytes and in human melanoma cells.  Forced expression of survivin blocks 
both caspase-dependent and -independent cell death in human melanocytes.
109
 In 
melanoma cells, our lab has demonstrated that survivin can protect against caspase-
independent apoptosis.
110
  Numerous studies have demonstrated the pro-apoptotic activity 
of dominant-negative survivin mutants in melanoma cells which increase the sensitivity 
to cytotoxic drugs in vitro,
91
 and reduce melanoma tumor growth in vivo.
83
  Using a 
mouse model with melanocyte-specific expression of survivin, our lab also demonstrated 
that survivin not only confers protection against apoptosis, but also promotes the 
development of UV-induced melanoma and tumor metastasis to lymph nodes.
111
 
 
A novel role for survivin: promotion of cellular motility
9
 
Cell motility encompasses both migration and invasion, which are key aspects of 
the metastatic process.
27
 Both migration and invasion require signaling events within the 
cell and with the extracellular matrix for navigation of tumor cells within their 
microenvironment and to distant sites. Recent studies have implicated survivin in these 
processes, which may underlie its role in promoting cancer metastasis. Mehrotra et al., 
using the breast adenocarcinoma line MDA-MB-231, showed that survivin co-operatively 
binds XIAP and mediates both cell invasion as well as metastasis in vivo, independent of 
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its anti-apoptotic function.
107
 Survivin-mediated invasion was integrin-independent and 
required activation of NF-κB and cell motility kinases FAK and Src.107 
My work has shown that survivin enhances cell migration and invasion of human 
melanoma cells.
48
 In our system, survivin promotion of motility was found to be 
dependent on activation of the Akt signaling pathway and upregulation of α5 integrin 
(which both occur following survivin expression in melanocytes or its over-expression in 
melanoma cells), as blocking either of these molecules abrogated survivin-enhanced 
migration.
48
  Knockdown of survivin by RNAi, under conditions where apoptosis was not 
induced, further demonstrated that survivin is required for constitutive migration and 
invasion of melanoma cells.
48
 An additional finding was that survivin-mediated 
promotion of melanoma cell invasion is also dependent on activation of the MAPK 
pathway, as evidenced by blocking with inhibitors of Erk phosphorylation.
48
  By contrast, 
over-expression of survivin is not consistently associated with Akt activation or α5 
integrin upregulation in other (nonmelanoma) cell lines (J. McKenzie, T. Liu and D. 
Grossman, unpublished).  
Survivin enhanced cell motility and invasion are dependent on the activation and 
function of cell adhesion receptors known as Integrins.
108
 The following subsection will 
describe these cells surface receptor proteins and their impact in cancer development and 
metastasis. 
 
Biology of integrins 
Integrins are a family of cell adhesion proteins consisting of α and β subunits.108 
They are cell surface transmembrane receptors that recognize and bind to extracellular 
matrix (ECM) proteins like fibronectin, laminin, and vitronectin.
109
 There are eighteen α 
24 
 
subunits and eight β subunits, which heterodimerize in twenty-four different 
combinations to enable ligand specificity and cell-type specific expression patterns.
110, 111
  
Integrin activation is regulated by ligand-binding affinity; the dynamics of which control 
cell adhesion and migration, ECM assembly and remodeling, and 
mechanotransduction.
112
 Consequently, integrin activity contributes to embryonic 
development, and to diseases such as cancer.  
 High ligand-binding affinity denotes integrin activation, while low ligand-binding 
affinity results in integrin inactivation.
113
 In their role as major cell surface adhesive 
receptors, integrins mediate bi-directional signaling across the plasma membrane to 
facilitate varying cellular functions (Figure 1.7). In what is termed ‘inside-out’ signaling, 
an intracellular activator (ex. Talin), binds to the cytoplasmic tail of integrins, resulting in 
conformational changes in the extracellular domain. Consequently, the extracellular 
ligand-binding affinity is increased (integrin activation).
112
 Inside-out signaling controls 
interactions between integrins and the ECM to allow for regulation of cell migration, and 
ECM assembly and remodeling.
112
 
  ‘Outside-in’ signaling allows for the flow of information from external stimuli to 
the inside of the cell. It is activated by ligand binding to the extracellular domain of 
integrins (Figure 1.7).
114
 Ligand binding results in conformational changes in integrins 
that cause ‘clustering,’ which is the assembly of integrin heterodimers into hetero-
oligomers to increase avidity.
115
 Once activated and clustered, integrins mediate an array 
of intracellular changes. Immediate changes result in cytoskeletal rearrangements that 
allow cells to initiate migration and invasion.
116
 More long-term effects of outside-in 
signaling include changes in signaling pathways and gene expression that regulate cell  
25 
 
  
Figure 1.7 Bi-directional signaling of integrins. During inside-out signaling, activator 
proteins like Talin, bind to the integrin cytoplasmic tail of integrins. The subsequent 
conformational change results in increased extracellular ligand-binding activity of 
integrins. This controls processes like cell adhesion and migration. Integrins also transmit 
signals from the extracellular environment to the inside of the cell (outside-in). This is 
initiated by ECM protein ligand binding to integrins. Subsequent clustering of integrin 
heterodimers results in changes in cytoskeletal proteins and cellular signaling networks 
that control cell polarity, gene expression, proliferation and survival.  
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survival, growth, and proliferation.
115
 Though theoretically separated, integrin bi-
directional signaling events are intimately linked, and can have feedback effects on each 
other.
112
 
 
Integrin function in cancer 
Tumor development and metastasis is dependent on the orchestration of complex 
cellular processes (Figure 1.6). Considering the fundamental role played by integrins in 
cell adhesion, growth, motility, and survival, deregulation of integrin signaling may 
facilitate a number of key steps in the metastatic process. Mutations in genes encoding 
integrins have not been observed in cancers to date. Instead, aberrant expression of 
integrins increases the aforementioned cellular functions, thereby contributing to tumor 
development and metastasis.
117
 Integrin expression has been shown to be heavily 
correlated with tumor development and poor patient prognosis in a number of 
malignancies.
118-120
 During tumor progression, malignant cells change the type and levels 
of integrins expressed depending on the microenvironmental cues encountered.
121
  
 Tumor cells are able to manipulate the expression levels of integrins by using the 
bi-directional signaling capacity of integrins, and through interaction with components of 
signaling pathways like MAPK and PI3K/AKT.
117
 Outside-in signaling can trigger 
MAPK and PI3K/AKT-mediated intracellular and gene expression changes which 
promote tumorigenesis.
122
 This can also produce a reciprocal effect with inside-out 
signaling eliciting changes in integrin expression that promote metastasis through: 
inhibition of apoptosis, induction of proliferation, ECM remodeling, migration and 
angiogenesis.
123, 124
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 Numerous studies have documented the multifaceted ways in which integrins 
contribute to tumor metastasis.
125-127
 In breast cancer, β1 integrin expression is associated 
with metastasis and reduced sensitivity to cytotoxic therapies.
128
 Inhibition of β1 integrin 
resulted in reduced tumor growth via induction of apoptosis.
129
 αvβ3 integrin has been 
shown to increase cellular proliferation of ovarian cancer cells in an integrin-linked 
kinase-dependent manner.
130
 Integrin-linked kinase (ILK) binds to β3 integrin and 
provides a bridge between integrin signaling and growth factor signaling pathways, as its 
phosphorylation of AKT contributes to proliferation through activation of the PI3K/AKT 
pathway.
131
  
In melanoma, the transition from RGP to VGP is associated with expression of 
αvβ3 integrin.
132
 αvβ3 integrin regulates the activity of Matrix Metalloproteinase-2 (MMP-
2), whose degradation of the basement membrane facilitates tumor invasion.
133, 134
 
Additionally, β3 integrin promotes melanoma growth and metastasis by regulating tumor 
cell survival.
126
 
AKT-dependent upregulation of α5 integrin also causes increased melanoma cell 
motility.
48
 Expression of α5 integrin in ovarian and lung cancers has been shown to 
increase metastasis.
135, 136
 In other settings, α5 integrin appears to act as a tumor 
suppressor. In colorectal cancer, α5 integrin downregulates expression of Her-2, and this 
causes decreased proliferation and tumorigenicity.
137
 
The results in my dissertation will focus on the activities of Survivin and α5 
integrin and their effects on melanoma cell motility and metastasis. The research 
presented will show that Survivin overexpression in melanoma cells results in 
28 
 
upregulation of α5 integrin. The increased levels of α5 integrin promote cell motility and 
colony formation in vitro, as well as metastasis in vivo. 
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Supplemental information 
Antibodies for Western blotting include Survivin (ref. 17) (1:1000), β-Actin 
(1:30,000; A-3853, Sigma), α-tubulin (1:1000, CP-06, Calbiochem-EMD Chemicals), α1 
integrin (1:1000, sc-10728, Santa Cruz Biotechnology), α2 integrin (1:1000; #611016, 
BD Biosciences), α3 integrin (1:1000; AB1920, Millipore), α5 integrin (1:1000, #47051, 
Cell Signaling Technology), α6 integrin (1:1000; MAB1356, Chemicon), αV integrin 
(1:1000; #611012, BD Biosciences), β1 integrin (1:1000; #610467, BD Biosciences), β3 
integrin (1:1000; #611140, BD Biosciences), β4 integrin (1:1000; #611232, BD 
Biosciences), E-cadherin (1:500, #610181, BD Transduction Laboratories), fibronectin 
(1:000, #610077, BD Transduction Laboratories), vimentin (1:500, sc32322, Santa Cruz 
Biotechnology), β-catenin (1:1000, #9582, Cell Signaling Technology), Akt (1:1000, 
#4619S, Cell Signaling Technology), phosphorylated (Ser473) Akt (1:1000, #9271L, Cell 
Signaling Technology), Erk1/2 (1:1000, #4675, Cell Signaling Technology), and 
phosphorylated Erk1/2 (1:1000, #4370S, Cell Signaling Technology). 
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Supplemental figures 
 
 
Supplemental figure S2.1 Survivin expression confers only modest protection against 
anoikis.  Human melanocytes were infected with pAd-GFP or pAd-Surv, then 24 h later 
were plated into Polyhema-coated wells.  A, Western blot demonstrating forced survivin 
expression in melanocytes 48 h after pAd infection.  B, Cells (pAd-Surv) adhere to 
control but not to Polyhema-coated dishes.  C, Cells were stained with propidium iodide 
and analyzed by flow cytometry 48 h after plating.  Representative histograms with bars 
indicating sub-G1 apoptotic fraction are shown. D, Quantitation of apoptotic fractions, 
based on triplicate determinations.  *P<.01. 
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Supplemental figure S2.2 Representative images of migrating melanocytes and 
melanoma cells.  A, DAPI-stained melanocytes (Mels) and melanoma cells (LOX, YU8) 
that were infected with pAd-GFP or pAd-Surv viruses, then allowed to migrate through 
transwell inserts.  B, DAPI-stained melanoma cells (LOX, YU8) that were transfected 
with scrambled (Scr) or survivin-specific RNAi prior to transwell assay.  
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Supplemental figure S2.3 Survivin expression does not alter markers of EMT.  A, 
Melanocytes were infected with pAd-GFP or pAd-Surv for 48 h. 4C7 melanoma cells 
were cultured for 48 h in the presence (tet+) or absence (tet-) of tet to repress or induce 
survivin over-expression, respectively.  Cell lysates were analyzed by western blotting.  
B, Melanocytes infected with pAd-GFP or pAd-Surv for 48 h were plated onto 
coverslips, stained for β-catenin (1:100 dilution for 1 h) then Texas Red-conjugated goat 
anti-rabbit IgG (2 μg per ml for 30 min).  
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Supplemental figure S2.4 Effect of Akt and MAPK pathway inhibition on survivin-
enhanced motility. A, YU2 melanoma cells were infected with pAd-GFP or pAd-Surv, 
then 24 h later treated with diluent, 6 μM PI3K inhibitor wortmanin, or 50 μM Erk 
inhibitor PD98059. After 24 h, cells were subjected to western blotting. B, YU2 and LOX 
melanoma cells were infected with pAd-GFP or pAd-Surv, then 24 h later treated with 
diluent or 6 μM PI3K inhibitor wortmanin.  After 24 h, cells were placed in transwells 
and assessed for migration (24 h) in the transwell assay. Error bars represent SEM of 
three determinations.  *P=.002, **P=.04.  C, YU2 and LOX cells were infected with 
pAd-GFP or pAd-Surv, then 24 h later treated with diluent or 50 μM Erk inhibitor 
PD98059. After 24 h, cells were placed in chambers and migrating (left) or invading 
(right) cells were quantitated 24 and 48 h later, respectively.  Error bars represent SEM of 
three determinations.  *P=.004, **P=.002.  ns, not significant. 
 
59 
 
 
Supplemental figure S2.5 Akt knockdown blocks survivin-enhanced motility.  A, LOX 
cells were infected with pAd-GFP or pAd-Surv, then 24 h later transfected with either 
scrambled (Scr) or Akt-specific siRNA. After 48 h, cell lysates were subjected to western 
blotting.  B, LOX cells were infected with pAd-GFP or pAd-Surv, then 24 h later 
transfected with either scrambled (Scr) or Akt specific siRNA.  After 24 h, cells were 
placed into chambers for motility assays and migrating (24 h, left) and invading (48 h, 
right) were quantitated.  Error bars represent SEM of three determinations.  *P=.001, 
**P=.02.  
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Supplemental figure S2.6 Effect of α5 integrin blocking antibodies on survivin-
enhanced invasion.  LOX melanoma cells were infected with pAd-GFP or pAd-Surv 
viruses, then after 24 h were added to Matrigel-coated inserts in the presence of 
antibodies against α5 or α5β1 as indicated. Media was replaced after 3 h, then invading 
cells were quantitated 48 h later.  Error bars represent SEM of three determinations. ns, 
not significant.  
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Abstract 
Survivin is an apoptotic and mitotic regulator that is overexpressed in melanoma, 
and a poor prognostic marker in patients with metastatic disease.  We recently showed 
that survivin enhances melanoma cell motility through Akt-dependent upregulation of 5 
integrin.  However, the functional role of survivin in melanoma metastasis is not clearly 
understood.  We found that overexpression of survivin in LOX and YUSAC2 human 
melanoma cells increased colony formation in soft agar, and this effect was abrogated by 
knockdown of 5 integrin by RNA interference.  We employed melanoma cell xenografts 
to determine the in vivo effect of survivin overexpression on melanoma metastasis. While 
survivin overexpression did not affect primary tumor growth of YUSAC2 or LOX s.c. 
tumors, or indices of proliferation or apoptosis; it significantly increased expression of 5 
integrin in the primary tumors and formation of metastatic colonies in the lungs.  
Additionally, survivin overexpression resulted in enhanced lung colony formation 
following i.v. injection of tumor cells.  Importantly, in vivo inhibition of 5 integrin via 
intraperitoneal injection of an 5β1 integrin-blocking antibody significantly slowed tumor 
growth and reduced survivin-enhanced pulmonary metastasis.  Knockdown of 5 integrin 
in cells prior to i.v. injection also blocked survivin-enhanced lung colony formation.  
These findings support a direct role for survivin in melanoma metastasis which requires 
5 integrin, and suggest that inhibitors of 5 integrin may be useful in combating this 
process. 
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Introduction 
Melanoma arises from epidermal melanocytes, and is the deadliest type of skin 
cancer, due to its high propensity for metastasis.
1
  Metastatic spread of tumor cells from a 
primary tumor to secondary organs is a highly specialized program that involves tumor 
cell migration, survival in the circulation, extravasation, and colonization of distant sites.
2
  
Despite recent therapeutic breakthroughs for metastatic melanoma with the approval of 
the BRAF kinase inhibitor Vemurafenib
3
 and the anti-Cytotoxic T-Lymphocyte-
associated Antigen 4 (CTLA4) monoclonal antibody Ipilimumab,
4
 there still remains a 
dismal prognosis for patients with advanced disease as in the majority of patients their 
tumors develop mechanisms of resistance.
5, 6
  Therefore, defining molecular mechanisms 
that govern melanoma progression may aid the development of more effective 
therapeutic strategies for combating melanoma metastasis. 
 Survivin, an inhibitor of apoptosis protein (IAP), is overexpressed in melanoma 
and has been identified as a biomarker of poor prognosis in metastatic disease.
7, 8
  
Survivin is expressed embryonically, silenced in most adult tissues, and aberrantly 
reactivated in malignant cells.
9
  Both anti-apoptotic and pro-mitotic roles for survivin 
have been described in malignancies including melanoma.
10, 11
  However, the role of 
survivin in melanoma metastasis has not been elucidated.  We previously reported that 
survivin is required for constitutive melanoma cell motility and its overexpression 
promotes motility through the Akt-dependent upregulation of 5 integrin.
12
  These studies 
suggested a potential alternate role for survivin, independent of apoptotic or mitotic 
regulation, in melanoma metastasis. 
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Integrins are a family of -β heterodimeric transmembrane proteins which act as 
receptors for cell adhesion molecules, and mediate bi-directional signaling between cells 
and the extracellular matrix.
13
  The diverse pairings of  and β integrin subunits regulate 
signaling pathways that regulate proliferation, differentiation, apoptosis and motility,
14
 
suggesting a role for integrin-mediated signaling in tumor cell development and 
metastasis.  Indeed, integrin expression is associated with metastatic phenotype in 
melanoma,
15
 and signaling through V3 integrin can promote melanoma metastasis in 
mice.
16
  As noted above, we previously implicated α5 integrin in survivin-enhanced 
melanoma cell motility in vitro,
12
 suggesting a potential role for this integrin in 
melanoma metastasis in vivo. 
Here we demonstrate that survivin promotes melanoma metastasis in vivo in an 5 
integrin-dependent manner.  In this study, we investigated the effect of survivin on 
melanoma metastasis using of an orthotopic mouse model with melanoma cells 
overexpressing survivin. We found that survivin overexpression resulted in upregulation 
of α5 integrin expression in vivo, and enhanced colony formation and metastasis to the 
lungs following either s.c or i.v. injection.  These pro-metastatic effects of survivin were 
dependent on tumor cell expression of α5 integrin. 
 
Materials and methods 
 
Cell culture 
Human melanoma cell lines (LOX, and YUSAC2), were maintained and passaged 
as previously described.
12
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Survivin-expressing lentivirus 
The survivin gene was PCR-amplified from human melanocyte cDNA.  The PCR 
product was cloned into pSC-B-Amp/Kan (Stratagene, Agilent Technologies, Santa 
Clara, CA), confirmed by sequencing, and then subcloned into the modified pEI2 
lentiviral expression vector obtained from Bryan Welm (Huntsman Cancer Institute, Salt 
Lake City, UT) which has been described previously.
33
  Validation of the lentiviral 
construct and production of the virus were carried out as described.
34
  For melanoma cell 
infection, 8 μg per mL Polybrene (AB01643-00001, Natick, MA) were added as a 
lipophilic reagent.  Cells were maintained in culture as stable lines which consisted of 
>95% GFP-positive cells. 
 
Immunoblotting 
Western blotting was performed as previously described.
12
 
 
Invasion and migration assays 
Transwell migration assays were performed as previously described.
12
 
 
Colony formation assay 
The underlayer mix was created by mixing equal parts of a 1.6% SeaPlaque 
Genetic Technology Grade (GTG) agarose (50111, Lonza, Allendale, NJ) solution with 
2X Iscove’s medium (12200-036, Invitrogen Life Technologies, Grand Island, NY) 
containing 20% FBS and 2% penicillin-streptomycin-glutamine (PSG, Invitrogen), to 
give a final underlayer mix of 0.8% GTG agar with 10% FBS and 1% PSG.  Underlayer 
mix (2 mL) was poured into sterile 6-cm plates, and allowed to solidify on a level surface 
at 4°C.  The cell layer, consisting of 5 x 10
5
 (LOX) or 2.5 x 10
5
 (YUSAC2) cells in 
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Iscove’s medium containing 0.4% GTG agarose, 5% FBS, and 0.5% PSG in 5 mL was 
gently poured onto the solidified underlayer in each plate.  Plates were incubated at 37 
o
C, monitored daily, and media was replenished as needed to prevent dehydration of the 
agarose.  After 11 d, colonies were photographed and quantitated using ImageJ software.  
We found that 11 d was the optimal time for growth using these cell lines.  For soft agar 
assays incorporating RNAi, cells were seeded into agar 24 h after transfection with a 
scrambled or an α5 integrin-specific siRNA.   The oligonucleotides and RNAi transfection 
protocol are previously described.
12
 
 
Mice 
NOD.CB17/SCID mice were obtained from Jackson Laboratories (Bar Harbor, 
ME).  All procedures were approved by the Institutional Animal Care and Use 
Committee (IACUC) at the University of Utah. 
 
Spontaneous metastasis assay 
A total of 2 x 10
6
 cells in 0.25 mL PBS were injected s.c. into the right flank.  
Once tumors could be palpated, the long and short dimensions (d1, d2 respectively) were 
measured using digital calipers twice weekly.  Dimensions were later used to calculate 
tumor volume using the following equation V = d1 x (d2 x d2)/2.  Mice were sacrificed 
once tumors approached 2 cm
3 
or the experimental endpoint was reached, and then 
primary tumors and lungs were harvested.  For paraffin sections, tissues were fixed in 
10% neutral buffered formalin and later embedded in paraffin.  For cryosections, lungs 
were fixed in 4% paraformaldehyde and later embedded in Optimal Cutting Temperature 
compound (4583, Fisher Scientific, Pittsburgh, PA).  For assays involving blocking of α5 
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integrin, once tumor dimensions (d1 and d2) were approximately 0.5 cm, mice were 
injected i.p. twice weekly for 4 weeks with either M200 (Volociximab, 10 mg per kg) or 
the same dose of a control mouse IgG antibody (GWB-275D92, GenWay Biotech, San 
Diego, CA).  M200 is an α5β1 integrin-blocking antibody, kindly provided by Abbott 
Laboratories (Abbott Park, IL). 
 
Tail vein metastasis assay 
Mice were injected with 5 x 10
5
 cells in 0.25 mL PBS through the tail vein.  After 
24 h or 14 d, mice were euthanized, their lungs resected and fixed in 4% 
paraformaldehyde and then embedded in Optimal Cutting Temperature compound for 
cryosectioning.  The 24 h time point was used as an indicator of immediate extravasation, 
while 14 d served as a delayed time point as others have done.
35
   GFP-positive tumor 
cells were visualized by fluorescence microscopy. 
 
Immunohistochemistry 
Sections were de-waxed by citrus clearing solvent (8301, Fisher Scientific) and 
rehydrated using a decreasing ethanol gradient from 100% to 70%.  Antigen retrieval was 
performed by boiling for 20 min in sodium citrate (pH 6.0).  Immunohistochemistry was 
performed on 5-μm tissue sections using an immunoperoxidase method (K4010, Dako, 
Agilent Technologies), with rabbit polyclonal antibodies against human α5 integrin 
(1:300, HPA002642, Sigma, St. Louis, MO), or phosphohistone H3 (Ser10) (1:200, 9701, 
Cell Signaling Technology, Danvers, MA). 
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Tunel assay 
Paraffin-embedded tumor sections (5 μm) were dewaxed and rehydrated as 
described above. Sections were then incubated with proteinase K (01115879001, Roche, 
Genetech, San Francisco, CA) at 10 μg per ml for 1 h at room temperature.  Slides were 
then stained using the In Situ Cell Death Detection Kit TMR Red (12156792910, Roche), 
according to the manufacturer’s protocol. 
 
Statistics 
Data are expressed as SEM of multiple replicates.  All data presented are 
representative of at least two independent experiments.  P-values were generated by two-
tailed t-test using Prism Graphpad software (San Diego, CA). 
 
Results 
Survivin overexpression enhances melanoma cell metastatic 
potential 
To examine the functional role of survivin in melanoma metastasis, we utilized 
two human metastatic melanoma cell lines LOX and YUSAC2 (YU2) to generate in vivo 
models.  LOX and YU2 were stably transfected with a control lentivirus expressing GFP, 
or a lentivirus expressing GFP-tagged survivin.  Western blotting confirmed survivin 
overexpression and upregulation of 5 integrin in both lines (Figure 3.1a).  We then 
verified their increased migratory capacity in Transwell Migration Boyden chambers.  
Indeed, both LOX and YU2 lines transfected with GFP-survivin demonstrated a greater 
than two-fold increase in the number of migratory cells compared to their GFP-
transfected counterparts (Figure 3.1b). 
69 
 
 
 
Figure 3.1 Survivin promotes melanoma cell migration and colony formation.  (a) 
LOX and YUSAC2 (YU2) melanoma cells were infected with either GFP lentivirus 
(control) or a GFP-tagged survivin (Surv) expressing lentivirus, then 48 h later cell 
lysates were prepared and analyzed by western blotting for survivin, 5 integrin, and 
actin.  (b) LOX and YU2 cells stably overexpressing GFP or GFP-survivin (Surv) were 
added to transwell chambers (5 x 10
4
 cells per well) with fibronectin-coated inserts.  
Migratory cells (per high-power field, hpf) were quantified 24 h later.  Error bars 
represent SEM of triplicate determinations.  *P < 0.001, **P < 0.0001.  (c) LOX (5 x 10
5
) 
and YU2 (2.5 x 10
5
) cells overexpressing GFP or GFP-survivin (Surv) were seeded in 
soft agar for 11 d.  Cell colonies were then photographed and quantified.  Representative 
dishes for LOX cells shown at right.  Error bars represent SEM of triplicate 
determinations.  *P = 0.007, **P = 0.005.  (d) YU2 cells overexpressing GFP or GFP-
survivin (Surv) were transfected with scrambled (Scr) or 5 integrin-specific siRNA.  
After 24 h, cells were placed in soft agar assay as in (c).  Representative western blot 
showing knockdown of 5 integrin shown at right.  Error bars represent SEM of triplicate 
determinations.  *P = 0.003. 
70 
 
Next, we examined the effect of survivin overexpression on the capacity of 
melanoma cells to form anchorage-independent colonies in soft agar.  As shown in Figure 
3.1c, LOX and YU2 cells overexpressing GFP-survivin yielded more numerous colonies 
than GFP-transfected control cells.  To determine if 5 integrin is required for survivin-
enhanced colony formation, control and Survivin-overexpressing YU2 cells were 
transfected with a control siRNA or siRNA targeting 5 integrin prior to seeding in soft 
agar.  Knockdown of 5 integrin effectively negated survivin-enhanced colony formation 
(Figure 3.1d).  Thus these in vitro studies indicate that survivin enhances prometastatic 
activities in melanoma cells. 
 
Survivin overexpression increases melanoma pulmonary metastasis 
in vivo 
To determine whether survivin overexpression in melanoma cells could enhance 
metastasis in vivo, we performed a spontaneous metastasis assay in which control or 
survivin-overexpressing cells were injected s.c. into the flank of immunodeficient mice.  
Tumor size was monitored twice weekly for 6 weeks, then primary tumors were 
harvested and lungs were resected for analysis.  Tumors grew rapidly, but tumor growth 
was not significantly affected by survivin overexpression in YU2 cells (Figure 3.2a).  To 
further investigate the mechanics of tumor growth, we performed histological analyses to 
determine the proliferative and apoptotic indices of these tumors.  TUNEL staining of 
tumor sections indicated no significant difference in apoptotic rate in survivin-
overexpressing vs. control YU2 cells (Figure 3.2b).  Similarly, no significant differences  
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Figure 3.2 Survivin promotes metastasis of yusac2 melanoma cells in vivo.  (a) 
YUSAC2 (YU2) cells stably overexpressing GFP or GFP-survivin (Surv) were injected 
s.c. into the flank of immunodeficient mice.  Once tumors were palpable, they were 
measured twice weekly for 6 weeks.  Error bars indicates SEM of 4-5 mice per group.  
ns, not significant.  Results representative of two experiments performed.  (b) TUNEL 
staining was performed, and apoptotic cells per high power field (HPF) are indicated (left 
panel).  ns, not significant.  Representative images of GFP-positive tumor cells (green) 
and TUNEL-positive apoptotic cells (red) are shown (right panel).  (c) Staining tumor 
sections for phospho-histone H3 (pHH3) allowed quantification of proliferating cells per 
high power field (HPF) as indicated (left panel).  ns, not significant.  Representative 
images are shown (right panel).  (d) Representative images of immunostaining of tumor 
sections for 5 integrin.  (e) Quantification of GFP-positive metastatic foci in lungs from 
mice in (a) are indicated per high power field (HPF) (left panel).  Error bars indicate 
SEM.  *P = 0.006.  Representative images showing GFP-positive metastatic cells in 
lungs (right panel).  (f) Phospho-histone H3 immunostaining of lung sections per high 
power field (HPF) as indicated (left panel).  ns, not significant.  Representative images 
are shown (right panel).  All images in figure taken at x200 magnification. 
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were seen in proliferation as measured by phospho-histone H3 staining in survivin-
overexpressing vs. control cells (Figure 3.2c).  Immunohistochemistry for 5 integrin 
confirmed higher levels of expression in survivin-overexpressing vs. control YU2 tumors 
(Figure 3.2d).  Pulmonary metastases were quantified by counting GFP positive foci in 
serial lung sections.  Notwithstanding the similarity in tumor growth, a significant 
increase in the number of lung metastases was seen in mice bearing survivin-
overexpressing vs. control YU2 tumors (Figure 3.2e).  We could not identify apoptotic 
tumors cells in the lungs by TUNEL staining (not shown).  Importantly, there was no 
difference in proliferative activity of tumor cells in the lungs (Figure 3.2f), suggesting 
that the greater number of survivin-overexpressing cells in the lungs was a result of 
metastasis rather than expansion following metastasis.  Similar findings were observed in 
companion experiments with survivin-overexpressing and control LOX tumors 
(Supplemental Figure S3.2).  These results indicate that survivin overexpression in 
melanoma cells leads to increased expression of 5 integrin and promotes lung 
metastasis. 
Given that survivin promoted lung metastasis without affecting tumor growth; we 
next assessed the capacity of survivin-overexpressing cells to establish lung metastases 
following injection directly into the tail vein.  This approach bypasses the need to 
navigate from the primary tumor, and measures the ability of tumor cells to survive in the 
bloodstream, extravasate, and colonize the lung.
17
  We injected YU2-GFP or YU2-Surv 
cells into the tail vein, then sacrificed mice and resected the lungs to measure 
extravasated cells (24 h post injection) or metastatic colonies (14 d post injection).  Both 
control and survivin-overexpressing cells showed similar number of extravasated cells in 
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the lungs 24 h post injection (Figure 3.3a), suggesting that survivin overexpression does 
not affect melanoma cell survival in the circulation or capacity to extravasate in the 
lungs.  No difference in tumor cell proliferation in the lungs was observed either (Figure 
3.3b).  However, examination of the lungs 14 d following i.v. injection revealed a 
significant increase in lung metastases in mice injected with survivin-overexpressing cells 
compared to control cells (Figure 3.3c).  The lack of difference in pHH3 staining (Figure 
3.3d) confirmed that increased numbers of cells had become established in the lungs, 
rather than proliferating after reaching the lungs.  Thus while survivin overexpression 
does not appear to affect primary tumor growth or immediate extravasation of cells into 
the lungs, there is enhanced capacity of these cells to establish metastatic colonies in the 
lung. 
 
5 integrin is required for survivin-enhanced pulmonary metastasis 
Our finding that overexpression of survivin in primary tumors correlated with 
higher expression levels of 5 integrin (Figure 3.2d) is consistent with our previous in 
vitro finding that survivin overexpression results in upregulation of 5 integrin in 
melanoma cells.
12
  To determine if increased 5 integrin expression is critical for 
survivin-enhanced lung metastasis, we repeated the spontaneous metastasis assay using 
s.c. injected cells and incorporated an 5β1 integrin-blocking antibody (M200).  We first 
confirmed that M200 effectively blocked survivin-enhanced melanoma cell motility in 
vitro, while a control IgG antibody did not (not shown).  Mice with survivin-
overexpressing tumors (YU2-Surv) were injected i.p. with M200 or the control antibody 
twice weekly for four weeks, and compared to mice with YU2-GFP tumors injected with 
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Figure 3.3 Survivin overexpression enhances melanoma cell colonization of the 
lungs.  (a) YU2-GFP or YU2-Surv cells were injected into the tail vein of 
immunodeficient mice.  Mice were sacrificed 24 h later, and the lungs resected and 
cryosectioned.  Number of GFP-positive cells per high power field (HPF) was counted in 
lung sections.  Error bars indicate SEM from 5 mice.  ns, not significant.  Representative 
of two experiments performed.  (b) Proliferating tumor cells in the lungs from mice in (a) 
were assessed by phospho-histone H3 (pHH3) staining.  Error bars indicate SEM.  ns, not 
significant.  (c) YU2-GFP or YU2-Surv cells were injected as in (a), then mice were 
sacrificed 14 d later.  GFP-positive foci were quantified and expressed per high power 
field (HPF).  Error bars indicate SEM from 5 mice.  *P < 0.001.  Representative of two 
experiments performed.  (d) Phospho-histone H3 (pHH3) staining of lungs from mice in 
(c).  Error bars indicate SEM.  ns, not significant. 
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the control antibody.  We found that tumor growth was similar between YU2-GFP and 
YU2-Surv tumors in mice treated with the control antibody (Figure 3.4a, Supplemental 
Figure S3.3).  However, there was a significant reduction in the growth of YU2-Surv 
tumors in mice treated with M200 (Figure 3.4a, Supplemental Figure S3.3).  TUNEL 
analysis revealed that while the level of apoptosis was similar between the control 
antibody-treated groups, the survivin-overexpressing tumors in mice treated with M200 
contained significantly more apoptotic cells (Figure 3.4b).  Similarly, M200 treatment of 
YU2-Surv tumors was associated with decreased tumor cell proliferation (Figure 3.4c).  
Consistent with our findings in Figure 2d, YU2-Surv tumors exhibited higher levels of 5 
integrin compared to control tumors in animals treated with the control antibody (Figure 
3.4d).  However, expression of 5 integrin was noticeably reduced in YU2-Surv tumors 
from animals treated with M200 (Figure 3.4d).  Consistent with our findings in Figure 
3.2e, we found that among mice treated with the control antibody that those with YU2-
Surv tumors had more lung metastases than mice with YU2-GFP tumors (Figure 3.4e).  
Importantly, examination of the lungs from mice bearing YU2-Surv tumors treated with 
M200 revealed fewer metastatic lung colonies (Figure 3.4e).  Finally, we investigated 
whether the mitigating effect of 5 integrin inhibition on survivin-enhanced metastasis 
was related to, or independent of, decreased growth of the primary tumor.  To address 
this question, we examined the effect of knocking down enhanced 5 integrin expression 
in YU2-Surv cells on their capacity to form lung mets following i.v. delivery.  There was 
no precedent for administering M200 i.v., and we had shown that RNAi-mediated 
depletion of 5 integrin was effectively sustained for up to 11 d (Figure 3.1d).  As shown 
in Figure 3.4f, RNAi-mediated knockdown of 5 integrin abrogated the survivin- 
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Figure 3.4 Survivin-enhanced pulmonary metastasis is dependent on 5 integrin.  (a) 
YU2-GFP or YU2-Surv cells were injected s.c. into the flank of immunodeficient mice.  
Once tumors were palpable, mice were injected twice weekly with M200 or a control 
(IgG) antibody (10 mg per kg) as indicated for 4 weeks.  Error bars indicate SEM of 
tumor measurements in 8 mice per group.  *P < 0.001.  Representative of two 
experiments performed.  (b) TUNEL staining of tumors in (a) at experimental endpoint.  
Error bars indicate SEM of apoptotic cells per high power field (HPF) in 8 tumors per 
group.  *P < 0.0001.  (c) pHH3 staining of tumors in (a) at experimental endpoint.  Error 
bars indicate SEM of proliferating cells per high power field (HPF) in 8 tumors per 
group.  *P = 0.0005.  (d) Representative images of 5 integrin immunostaining of tumor 
sections from each group.  (e) Lungs from mice in (a) were sectioned and number of 
GFP-positive foci were quantified and expressed per high power field (HPF).  Error bars 
indicate SEM from 7-8 mice per group.  Lungs could not be recovered from one mouse in 
the Surv-IgG group.  *P < 0.001.  Representative of two experiments performed.  (f) 
YU2-GFP or YU2-Surv cells were transfected with scrambled (Scr) or 5 integrin-
specific siRNA.  After 24 h, cells were injected into the tail vein of immunodeficient 
mice.  Mice were sacrificed 14 d later, and the lungs resected and cryosectioned.  Number 
of GFP-positive cells per high power field (HPF) in lung sections is indicated.  Error bars 
indicate SEM from 5 mice.  *P < 0.0001.  Representative of two experiments performed.  
All images in figure taken at x200 magnification. 
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enhanced pulmonary metastasis.  These in vivo results support our hypothesis that 
survivin promotes melanoma cell metastasis in an 5 integrin-dependent manner. 
 
Discussion 
Survivin was originally identified as an inhibitor of apoptosis,
18
 although 
subsequent studies revealed it to be a bifunctional protein that regulates both apoptosis 
and mitosis.
19
  Survivin has been widely implicated in metastasis and chemoresistance in 
a number of malignancies including melanoma,
7, 8
 breast cancer,
20
 and colorectal 
cancer.
21
  We recently reported that survivin is required for constitutive motility of 
melanoma cells, and that survivin overexpression increases melanoma cell motility in 
vitro via upregulation of 5 integrin.
12
  Here we demonstrate that survivin can promote 
melanoma cell colony formation and metastasis to the lungs in an 5 integrin-dependent 
manner. 
The anti-apoptotic and mitotic regulatory functions of survivin depend on cellular 
context and compartmentalization of survivin signaling networks.
22
  In our earlier work, 
we showed that survivin depletion in melanoma cells reduced their motility without 
inducing apoptosis, and that promotion of motility in survivin-overexpressing cells was 
evident in the presence of a mitosis inhibitor.
12
  In our experimental in vivo system, 
enhancement of melanoma metastasis by survivin also appeared to be independent of any 
potential apoptotic or mitotic effects.  While survivin-overexpressing tumors were more 
metastatic, we did not observe significant differences in growth rates compared to control 
tumors.  The lack of effect of survivin overexpression on tumor growth, consistent with 
our finding of no alterations in either apoptotic or mitotic indices in the tumors, suggests 
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that the pro-metastatic effect of survivin could not be attributed to an effect on primary 
tumor growth.  When tumor cells were injected i.v., there was no immediate (at 24 h) 
effect of survivin overexpression on lung colonization, suggesting that the effect of 
survivin was not simply to increase cell survival in the bloodstream.  Rather, our results 
suggest that survivin promotes extravasation and survival (but not proliferation) of tumor 
cells that reach the lungs, as higher numbers of lung colonies were seen in mice 14 d 
following i.v. injection of survivin-overexpressing vs. control cells. 
We observed that the pro-metastatic effect of survivin overexpression was 
associated with increased tumor expression of 5 integrin. We previously noted that 5 
integrin expression was higher in metastatic compared to primary human melanoma cell 
lines, and is a critical regulator of cell motility downstream of survivin.
12
  Others have 
shown that 5 integrin increases ovarian cancer metastasis and its expression is predictive 
of metastasis and poor prognosis in ovarian cancer patients.
23, 24
  In melanoma, 5 
integrin promotes in vivo metastasis of murine B16F10 melanoma cells.
25
  Integrins 
mediate outside-in and inside-out signaling, which may impact cell growth and death, 
adhesion, and motility.
26
  Integrin-based interactions are also known to be involved in 
matrix degradation and remodeling, which can aid in tumor cell dissemination from the 
primary tumor.
27
  We considered the possibility that increased 5 integrin expression 
promoted dissemination of cells from the tumor into the bloodstream, thereby facilitating 
seeding of tumor cells in the lungs.  To address this issue, we attempted to quantify 
circulating tumor cells in blood from mice with survivin-overexpressing tumors by 
quantitative real time polymerase chain reaction for the human melanoma marker melan-
A.  However, we were unable to detect such circulating cells by this method in any of the 
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mice over the 6-week period of tumor growth with our limit of detection being 250 
melanoma cells in 0.25 mL blood (J.M., T.L. and D.G., data not shown). 
Nevertheless, our results suggest that survivin-mediated upregulation of 5 
integrin in tumors promotes subsequent colonization of tumor cells in the lungs.  We 
found that upregulation of 5 integrin is critical for survivin-enhanced lung metastasis, as 
evidenced by the reduction in pulmonary metastasis seen when 5 integrin was targeted 
with the antibody M200 (Volociximab).  M200 treatment had the concomitant effect of 
reducing tumor growth, associated with higher levels of apoptosis and lower levels of 
proliferation in tumor cells.  These findings are consistent with those of others showing 
that inhibitory antibodies against 5 integrin can decrease tumor growth,
28
 possibly by 
inducing apoptosis in tumor-associated endothelial cells.
29
  We believe that this 
diminished tumor growth, however, is unlikely to represent the basis for the decreased 
metastasis resulting from 5 integrin inhibition.  To address this issue, we employed the 
modified metastasis assay in which tumor cells are injected i.v. rather than into the skin, 
which bypasses the effect of the primary tumor on the establishment of lung metastases.  
We found that knockdown of 5 integrin in tumor cells prior to injection decreased 
survivin-enhanced lung colonization, suggesting that the reduced metastasis observed in 
the spontaneous metastasis assay was not solely due to the inhibitory effect of M200 on 
primary tumor growth. 
In summary, the results of this study support a direct role for survivin and 5 
integrin in promoting melanoma metastasis, and suggest that inhibitors of 5 integrin like 
M200 may be useful in combating tumor progression and melanoma metastasis.  Indeed, 
several clinical trials have been conducted examining the efficacy of M200 in metastatic 
80 
 
melanoma and other cancers. 
30-32
  A phase II trial of M200 in patients with metastatic 
melanoma found that when combined with dacarbazine, about half of the participants 
exhibited stable disease at eight weeks, while the remaining patients suffered progressive 
disease.
32
  It is not clear that dosing of M200 was fully optimized to block 5 integrin in 
metastatic tumors, and perhaps future trials combining agents that target 5 integrin and 
oncogenic kinases (such as BRAF) or immunomodulatory molecules (such as CTLA-4), 
may prove more fruitful. 
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Supplemental figures 
 
 
Supplemental figure 3.1 Representative images of mice following s.c. inoculation with 
YU2 or LOX cells overexpressing GFP or survivin.  Images were taken after 
approximately 6 weeks once mice were sacrificed. 
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Supplemental figure 3.2 Survivin promotes metastasis of LOX melanoma cells in vivo.  
(a) LOX cells stably overexpressing GFP or GFP-survivin (Surv) were injected s.c. into 
the flank of immunodeficient mice.  Once tumors were palpable, they were measured 
twice weekly for 6 weeks.  Error bars indicates SEM of 5 mice per group.  ns, not 
significant.  Results representative of two experiments performed.  (b) TUNEL staining 
was performed, and apoptotic cells per high power field (HPF) are indicated (left panel).  
ns, not significant.  Representative images of GFP-positive tumor cells (green) and 
TUNEL-positive apoptotic cells (red) are shown (right panel).  (c) Staining tumor 
sections for phospho-histone H3 (pHH3) allowed quantification of proliferating cells per 
high power field (HPF) as indicated (left panel).  ns, not significant.  Representative 
images are shown (right panel).  (d) Representative images of immunostaining of tumor 
sections for 5 integrin.  (e) Quantification of GFP-positive metastatic foci in lungs from 
mice in (a) are indicated per high power field (HPF).  Error bars indicate SEM.  *P < 
0.0001.  Representative images showing GFP-positive metastatic cells in lungs (right 
panel).  (f) Phospho-histone H3 immunostaining of lung sections per high power field 
(HPF) as indicated (left panel).  ns, not significant.  Representative images are shown 
(right panel).  All images in figure taken at x200 magnification. 
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Supplemental figure 3.3 Survivin-enhanced pulmonary metastasis is dependent on α5 
integrin. Representative images of mice bearing control tumors (YU2-GFP) or survivin 
overexpressing tumors (YU2-Surv) that were treated with M200 or a control antibody 
(IgG). 
 
CHAPTER 4 
 
SUMMARY AND PERSPECTIVES 
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Dissertation summary 
 Survivin is a nodal protein that has been demonstrated to intersect multiple 
pathways required for tumor development and progression.
1
 It has provided unique 
opportunities for basic and translational oncology, as it is a pro-oncogenic molecule that 
is not expressed in normal adult cells but is reactivated in malignant cells. Survivin 
function in the inhibition of apoptosis in tumor cells is well documented. Studies from 
our laboratory have demonstrated that survivin can protect melanocytes and melanoma 
cells from caspase independent and dependent apoptosis.
2, 3
 Additionally, inhibition of 
survivin induced spontaneous apoptosis in melanoma cells and reduced melanoma tumor 
growth.
4, 5
 While its importance in apoptosis goes without question, the fact that survivin 
is so intimately linked to a number of circuitries in the cell that work together to 
propagate and maintain tumors, suggests that it plays multiple roles in tumor 
development and metastasis.
6
 
 Thomas et al. showed in 2007 that melanocyte-specific expression of survivin in 
vivo decreased the susceptibility of melanocytes to UV-induced apoptosis, and 
surprisingly, also promoted metastasis.
7
 As is highlighted in the seminal review ‘The 
Hallmarks of Cancer,’ inhibition of apoptosis is an important feature acquired by cancer 
cells, which is key for metastasis.
8
 However, this function alone may not be sufficient to 
promote metastasis. Studies using in vivo tumor models of survivin expression in 
uroepithelium
9
 and in keratinocytes
10
 demonstrated that while survivin expression 
promoted tumorigenesis, no metastasis was detected. This suggests that in addition to its 
anti-apoptotic role in melanoma cells, survivin may promote metastasis through other 
mechanisms. This led us to think about the underlying functions of the cell that would 
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facilitate melanoma metastasis and how survivin may be involved in these processes. 
This chapter provides a summary of the main questions addressed in our studies of 
Survivin function in melanoma metastasis and the approaches used to answer said 
questions. 
 As was stated earlier in Chapter 1, metastasis requires migration and invasion of 
metastatic cells to allow navigation through the primary tumor and intravasation into the 
circulation; extravasation from vessels into target organs, and colonization of these 
secondary organs (Figure 1.7). To understand how survivin may be important in 
melanoma metastasis, we began by asking whether survivin expression in melanocytes 
and melanoma cells could affect cell motility. We used Transwell migration and Matrigel 
assays to determine the effect of survivin on migration and invasion, respectively. We 
found that survivin was sufficient for cell migration and invasion as its expression in 
melanocytes resulted in increased migration and invasion.
11
 We also found that the 
migratory and invasive capacity of melanoma cells was greatly enhanced following 
survivin overexpression.
11
 Given that survivin has a documented role in mitosis;
12, 13
 we 
asked the question of whether the increased motility effect of survivin was dependent on 
mitosis. To do that, we conducted the migration and invasion assays under conditions 
where mitosis was blocked by Mitomycin C, an agent that prevents DNA synthesis and 
therefore blocks cell division. Under these conditions, melanocytes and melanoma cells 
were able to migrate and invade more in response to increased levels of survivin. This 
implies that these pro-metastatic activities were being mediated independent of any 
potential effect on mitosis. We also demonstrated requirement of survivin for migration 
and invasion of melanoma cells through the use of RNA interference (RNAi).
11
 Under 
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conditions where apoptosis was not being induced by knockdown of survivin, we 
demonstrated that melanoma cells were less motile.
11
 As such, survivin may not be 
promoting melanoma metastasis solely through its role as an anti-apoptotic protein. 
 To further determine how survivin could enhance melanoma cell motility, we 
carried out microarray analyses of the gene expression profile of control (GFP-
expressing) and survivin-expressing human melanocytes (Appendix A.1). The profile 
revealed that genes involved in extracellular matrix (ECM) interactions, including α5 
integrin, were highly upregulated in survivin expressing cells (Appendix A.1). Cell 
adhesion molecules like integrins function to regulate cellular processes like migration 
and invasion.
14
 Therefore, we investigated whether survivin could enhance melanoma 
cell motility via regulation of integrins. By examination of the protein levels of a number 
of α and β integrins known to be expressed in melanoma,15 we detected that α5 integrin 
levels were elevated in response to survivin overexpression in melanoma cells.
11
 
Inhibition of α5 integrin by RNAi or by blocking antibody demonstrated that α5 integrin 
function was required for survivin-enhanced migration.  
Tumor cells are able to regulate the expression levels of adhesion molecules like 
integrins to transmit signals that help them to navigate away from the primary tumor.
16
 
Integrin control of cell movement is mediated by crosstalk with signaling pathways like 
MAPK, and AKT which as was discussed earlier are heavily altered in metastatic 
melanoma.
17, 18
 Additionally, studies have shown that inhibition of components of these 
signaling pathways can inhibit melanoma migration and invasion.
19, 20
  Our results also 
support this notion as we have shown that pharmacological inhibition of AKT blocks 
survivin mediated migration.
11
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We further examined the effect of survivin on melanoma metastasis by using an 
orthotopic mouse model. In this experimental system, melanoma cells stably 
overexpressing survivin were injected s.c. into NOD SCID mice and then tumor 
progression was monitored. These studies revealed that overexpression of survivin did 
not confer a proliferative advantage to tumors, nor did it inhibit apoptosis. However, 
survivin overexpression did result in increased expression of α5 integrin in primary 
tumors and increased tumor cell metastasis to the lungs. Experimental lung metastasis 
was also increased with overexpression of survivin. The increase in metastasis was 
dependent on α5 integrin, as blocking of α5 integrin by M200 (inhibitory antibody of α5β1 
integrin), reduced the growth of primary tumors and subsequently reduced tumor 
metastasis to the lungs. The reduction in metastasis in response to blockade of α5 integrin 
may be due to the reduced growth of the primary tumor. However, reduced metastasis 
may also be as a result of α5 integrin effect at the site of metastasis. In an experimental 
metastasis assay, tumor cells with reduced levels of α5 integrin were injected i.v. into the 
tail vein of NOD SCID mice. This allowed for examination of metastasis without the 
effects of a primary tumor. Our results showed that melanoma cells with less α5 integrin 
were not able to form metastatic colonies in the lung as well as melanoma cells 
expressing higher levels α5 integrin.  
 
Perspectives 
Survivin localizes to different subcellular compartments,
21, 22
 and this allows for a 
variety of posttranslational modifications including phosphorylation and ubiquitination.
23-
25
 Consequently, the various modifications may help to distinctly regulate survivin 
functions.
26
 The pro-metastatic roles of survivin may therefore be governed in a cell-type 
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specific and subcellular context specific manner. Evidence suggests that the 
cytoprotective function of survivin is carried out by the mitochondrial fraction.
26
 Survivin 
is phosphorylated on Serine-20 (Ser20) by Protein Kinase A (PKA) in the cytosol. 
Phosphorylation at this site disrupts the binding of Survivin to its antiapoptotic cofactor 
x-linked inhibitor of apoptosis protein (XIAP), thereby blocking its ability to mediate 
cytoprotection.
26
 However, PKA is unable to phosphorylate survivin in the mitochondria. 
Consequently, mitochondrial Survivin is able to bind to XIAP and inhibit apoptosis.
26
 
The antiapoptotic function of survivin may not be required for its effect on 
melanoma cell motility and metastasis. As we showed using in vitro studies, inhibition of 
survivin by RNAi reduced melanoma cell migration and invasion without induction of 
apoptosis.
11
 This is consistent with other studies that have also demonstrated that the 
antiapoptotic function of survivin is not required for tumor invasion and metastasis.
26, 27
 
In one study, a model of rat insulinoma INS-1 cells, in which stable transfection of 
survivin does not confer cytoprotection, was used to demonstrate increased tumor cell 
invasion.
27
 
There are key amino acid residues within the survivin structure that are essential 
for its antiapoptotic and mitotic functions.
28
 Mutation of these residues may help to better 
uncouple survivin function in apoptosis, mitosis and motility in melanoma. It is known 
that mutation of Threonine-34 to Alanine (T34A) in survivin disrupts dimerization of this 
protein and inhibits the antiapoptotic activity of survivin.
13, 29, 30
 Additionally, Ser20 is 
known to be important for survivin function in mitosis, as survivin is phosphorylated by 
Polo-like Kinase-1 (Plk1) at Ser20 to help control chromosomal alignment during 
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mitosis.
31
 These mutants could be utilized in our in vitro and in vivo models of melanoma 
motility and metastasis to better distinguish how survivin regulates melanoma metastasis. 
α5 integrin could be mediating survivin-enhanced metastasis on a number of 
levels in the metastatic cascade. In addition to facilitating tumor migration and invasion 
from the primary tumor, α5 integrin may also affect the survival of tumor cells in 
circulation. This could be one possible point of intersection between α5 integrin and 
survivin function as an anti-apoptotic protein. As an adhesive receptor, α5 integrin could 
direct association of melanoma tumor cells with platelets and leukocytes in the 
circulation. This may allow tumor cells to form small tumor emboli that aid in keeping 
tumor cells in target metastatic sites.
16
  Adhesion to target organ endothelium and 
extravasation for metastatic outgrowth could also be facilitated by the adhesive functions 
of α5 integrin. 
In addition to mediating cell motility, α5 integrin could also be facilitating 
colonization, or outgrowth at distant sites. For successful metastatic colonization to 
occur, tumor cells need to be able to interact with a foreign microenvironment.
32
 
Microenvironment components like fibroblasts, endothelial cells, and infiltrating 
inflammatory cells produce cytokines, chemokines, growth factors and proteases to 
which tumor cells will respond. In a reciprocal manner, tumor cells will also signal to the 
microenvironment to remodel it to favor tumor cell colonization.
32
 The bi-directional 
signaling capacity of integrins makes them amenable to mediating the interactions 
between tumor cells and the microenvironment in metastatic niches.
16
 
Survivin and α5 integrin share common functions that enable melanoma tumor 
cell metastasis. They are both implicated in tumor cell ability to resist apoptosis, and in 
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tumor cell invasion and migration. Intersection of survivin and α5 integrin with key 
signaling networks like MAPK and PI3K/AKT may also promote cell survival and 
proliferation. Therefore, it may be difficult if not impossible to discern the individual 
contributions of survivin and α5 integrin to the metastatic process in melanoma. 
 However, the studies in this dissertation clearly add credence to the importance of 
survivin and α5 integrin in melanoma metastasis. In our in vivo model of melanoma 
metastasis, we were able to utilize M200, which blocks α5β1 integrin function, to 
demonstrate the necessity of α5 integrin for survivin-enhanced metastasis.
11
 There have 
been a number of clinical trials conducted to determine the effect of M200 on metastatic 
melanoma, renal cell, and pancreatic cancers.
33-35
 These studies had mixed results with 
some patients showing partial responses to M200 but most were unresponsive or 
refractory to M200 treatment.  
Our studies may argue that the timing of intervention in these studies may be 
crucial for any real therapeutic value to be obtained with M200 treatment. In many of 
these studies, patients are being treated with M200 after metastases have become well 
established throughout the body and targeting of α5β1 at that point is ineffective. In our in 
vivo studies, inhibition of α5 with M200 early in tumor development, or through RNAi 
prior to lung colonization could stem metastatic spread and outgrowth. This suggests that 
the design of clinical trials based on M200 efficacy in curtailing or preventing metastasis 
needs to be optimized to allow for an earlier point of intervention. Perhaps, M200 could 
be used as an adjuvant therapeutic agent after resection of primary tumors where 
metastatic spread is indicated. It is possible that by blocking α5 integrin earlier in the 
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disease progression, many of the advantages that allow tumor cells to propagate and 
metastasize may be reduced. 
The combined effect of survivin and α5 integrin on metastasis may also be context 
dependent. We have shown that survivin upregulation of α5 integrin is conserved in a 
number of melanoma cell lines. And that α5 integrin is required for survivin-enhanced 
migration.
11
 In the SK-mel 28 melanoma cell line, where overexpression of survivin did 
not cause upregulation of α5 integrin, cell migration was not increased (Appendix B.1); 
further suggesting that α5 integrin is required to mediate survivin-enhanced motility. We 
investigated whether survivin upregulation of α5 integrin was also conserved in other 
tumor types. This relationship was not seen in cell lines derived from other tumor types 
such as breast, colon and Ewing’s sarcoma (Appendix C.1). Additionally, survivin 
expression in MCF-7 breast cancer cells resulted in increased liver metastasis in vivo.
27
 
However, the mechanism of action was alternate to α5 integrin. It was found that survivin 
increased metastasis through activation of NF-κB and increased expression of activated 
Focal Adhesion Kinase (FAK).
27
 This suggests that there is potentially a unique 
mechanism by which survivin is able to mediate melanoma metastasis via α5 integrin. 
In our studies, we monitored melanoma metastasis to the lungs. However, it is 
known that in addition to the lungs, melanoma also metastasizes to the brain, liver and 
bones.
36
 Therefore it is possible that in our model, lung metastasis may be an incomplete 
picture and α5 integrin may also mediate survivin-enhanced melanoma metastasis to other 
organs in the body. While we have shown a requirement for α5 integrin in survivin-
enhanced melanoma metastasis, key questions remain unanswered about the mechanisms 
involved. Potential future directions for this project will be discussed in the next section. 
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Future Directions 
 One important question raised by these studies is: how is upregulation of α5 
integrin in the tumor cells allowing for metastatic spread? α5 integrin may be remodeling 
the ECM to allow tumor cells to move more freely out of the tumor and into the 
circulation to be transported to other organs. One way to address this question would be 
to determine the effect of α5 integrin on matrix remodeling by assessing the activity of 
proteolytic enzymes like matrix metalloproteinases (MMPs). MMPs are a family of 
endoproteinases whose functions include degradation of ECM proteins like fibronectin, 
laminin and collagen.
37
 
Binding of cell surface receptors like integrins to their ECM ligands can initiate 
cell signaling events that modulate the expression and activity of MMPs.
38
 MMPs are 
thought to facilitate tumor invasion and metastasis through several mechanisms that 
include the enzymatic activity of MMPs on ECM proteins. Proteolytic processing by 
MMPs removes the physical barrier to tumor cell movement, as they degrade basement 
membranes.
37
 Secondly, MMPs interact with integrins to regulate cell adhesion, which 
undergoes dynamic changes as tumor cells move from primary tumors to metastatic 
sites.
37
 In cervical cancer cells, α5β1 integrin binding to fibronectin has been shown to 
increase the expression and proteolytic activity of MMP-2 and MMP-9.
38
 This effect was 
mediated by activation of AKT and NF-κB signaling.38 Therefore, the survivin mediated 
upregulation of α5 integrin in melanoma cells, may be promoting metastasis through 
increased MMP activity in the primary tumor. 
 Another potential research direction could be focused on how survivin is able to 
cause upregulation of α5 integrin. We showed that survivin upregulation of α5 integrin is 
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dependent on phosphorylation of AKT.
11
 PTEN negatively regulates the phosphorylation 
of AKT and a recent study has shown that the tumor suppressor function of PTEN 
involves silencing of survivin gene expression.
39
 This study also suggested that in a 
negative feedback loop, survivin expression in malignant cells can silence PTEN gene 
expression and function.
39
 Therefore, survivin expression could relieve PTEN inhibition 
of AKT phosphorylation, thereby leading to upregulation of α5 integrin (Figure 4.1). This 
AKT dependent upregulation of α5 integrin may be at the transcriptional level. 
Transcription factors for α5 integrin include AP-1, SP-1and NF-1,
40
 some of which are 
known targets of the AKT pathway.
41, 42
  
 Other areas of research interest could include the translational and post-
translational regulation of α5 integrin. The significant increase in α5 integrin levels in 
survivin-expressing melanoma cells over control cells suggests that survivin may regulate 
α5 integrin at the protein level. Studies have demonstrated that protein levels of α5 integrin 
are controlled through endocytic and exocytic cycling between the cytosol and the cell 
surface.
43
 This process of integrin recycling controls whether integrins are targeted for 
degradation by ubiquitination, or whether they are returned to the cell surface.
43
 It has 
been reported that Protein Kinase B (AKT) enhances cell migration through regulation of 
Glycogen Synthase Kinase-3β (GSK-3β) dependent α5 integrin recycling.
44
 Therefore, 
one area of study could examine the role of survivin in AKT mediated recycling of α5 
integrin, as this could be one way through which survivin is able to upregulate α5 integrin 
expression in melanoma and thereby increase motility and metastasis. 
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Figure 4.1 Integration of survivin and α5 integrin function in melanoma. This is a 
potential model for survivin and α5 integrin function. Increased expression of survivin in 
melanoma cells can lead to upregulation of α5 integrin by relieving PTEN inhibition of 
AKT activation. Downstream of AKT activation, gene expression changes can lead to 
increased α5 integrin to help facilitate cell motility and metastasis. In melanoma, aberrant 
RAS signaling can also activate the PI3K/AKT pathway. Additionally, integrin outside-in 
signaling can interact with the PI3K/AKT pathway via Focal Adhesion Kinases (FAK) to 
further stimulate this signaling pathway. 
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The bi-directional signaling of integrins that intersects with survivin function and 
with growth signaling pathways like PI3K and MAPK, can present yet another avenue for 
improving melanoma therapies. The α5β1 integrin inhibitory antibody M200, which was 
used in the in vivo experiments of this study, has had mixed success in clinical trials 
(discussed in Chapter 3). As was addressed in the introductory chapter, resistance to RAF 
inhibition is a common problem associated with the use of Vemurafenib. In one 
mechanism of resistance, upregulation of RAS can result in activation of the AKT 
pathway and may lead to downstream upregulation of α5 integrin. Therefore, targeting of 
RAF not only in combination with MEK, but also with α5 integrin may help combat 
melanoma metastasis. The work presented in this dissertation adds another piece to the 
puzzle and further illustrates the intricacies involved in melanoma metastasis.  
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Figure A.1 Gene expression profile of survivin expressing melanocytes. Melanocytes 
were isolated from four different donors and infected with pAd-GFP or pAd-Surv. After 
48hrs, total RNA was isolated from each group, and run in quadruplicate on Agilent 
Human Genome arrays. Statistical analysis of the normalized log-transformed data was 
performed using GeneSifter Software. Comparisons were made of paired samples to 
control for inter-donor variability, and pair-wise t-tests were performed with an adjusted 
p-value of ≤ 0.05. (A) Heatmaps of differentially affected (p<0.05) pathway genes.  (B) 
Validation of selected genes by qRT-PCR.  Triplicate determinations of relative RNA 
levels (each normalized to GAPDH = 1.0, dotted line) in pAd-Survivin - compared to 
pAd-GFP-infected cells.  GAPDH was not affected by survivin expression.  Error bars 
indicate SEM. 
 
APPENDIX B 
 
MIGRATION OF SK-MEL 28 MELANOMA CELLS 
 OVEREXPRESSING SURVIVIN 
107 
 
 
Figure B.1 Migration of survivin overexpressing sk-mel 28 melanoma cells. SK-mel 
28 melanoma cells were infected with a control adenovirus expressing GFP (SK-mel 28 
GFP), or an adenovirus expressing survivin (SK-mel 28 Surv). 24h later cells were 
treated for one hour with 10 μg/ml Mitomycin C to inhibit cell division. 15 000 cells 
were then transferred to each of three Transwell chambers which had been coated 
overnight with 10 μg/ml fibronectin. Cells were allowed to migrate for 24 hours. 
Migratory cells were then fixed, stained and quantitated. 
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Figure C.1 Survivin and α5 integrin expression in non-melanoma cell lines. A673 
Ewing’s sarcoma cells (1,2), HEK 293 transformed human embryonic kidney cells (3,4), 
T47D breast cancer cells (5,6), Hacat immortalized human keratinocytes (7,8), HCT 116 
colon cancer cells (9,10), and MDA-MB-231 breast cancer cells (11,12) were infected 
with a control adenovirus expressing GFP (odd number lanes), or an adenovirus 
expressing survivin (even number lanes). 48h later, cell lysates were generated and 
subjected to western blot analysis for expression levels of survivin, and α5 integrin. 
Expression of total AKT was used as a loading control. 
